Key result
Optimal antithrombotic therapy post-TAVI lacks clear evidence to balance embolic and bleeding risks.
Why the study?
There is no clear evidence on the best antithrombotic regimen before, during, and after TAVI despite recognition of stroke and bleeding risks.
This review highlights the ongoing uncertainty and discusses mechanisms regarding the optimal antithrombotic regimen for patients undergoing TAVI to balance stroke and bleeding risks.
Answers are grounded in this paper and cite their sources.
TAVI antithrombotic regimens lack clear evidence; leaves open the need for RCTs to define optimal therapy balancing thrombosis and bleeding.
The issue of stroke and bleeding events following transcatheter aortic valve implantation (TAVI) and its relation with antithrombotic regimens before, during and after the procedure is increasingly recognized as an important issue. While dedicated trials are ongoing, there is no clear evidence at present on the best antithrombotic regimen in the context of TAVI. In this article, we will go through the mechanisms involved in embolic and bleeding complications of TAVI, and we will discuss the key aspects of antithrombotic treatment in patients undergoing TAVI.
No takes yet. Share an insight, caveat, or question.
Barbanti et al. (2015) conducted a review in Transcatheter aortic valve implantation (TAVI). Antithrombotic therapy was evaluated. This review discusses the mechanisms of embolic and bleeding complications following TAVI and highlights the current lack of clear evidence regarding the optimal antithrombotic regimen.
Synapse has enriched 10 related papers. Consider them for comparative context: